南方医科大学学报Issue(3)：446-449,4.DOI:10.3969/j.issn.1673-4254.2015.03.27
吉非替尼与厄洛替尼在EGFR基因敏感突变晚期NSCLC患者一线治疗中的疗效比较
Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
摘要
Abstract
Objective To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. Methods Fifty patients with untreated advanced EGFR mutation-positive NSCLC were randomly divided into gefitinib group (n=27) and erlotinib group (n=23). The progression-free survival, objective response rate and disease control rate were evaluated to compare the efficacy of gefitinib and erlotinib. Results There were no significant differences in the objective response rate (P=0.711) and disease control rate (P=0.861) between the two groups. The progression-free survival of gefitinib group and erlotinib group was 8.0 months and 10.0 months, respectively. The efficacy of the two drugs was similar (P=0.293). Conclusion There is no significant differences between gefitinib and erlotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC.关键词
晚期非小细胞肺癌/吉非替尼/厄洛替尼/EGFR基因/突变位点Key words
advanced non-small-cell lung cancer/Gefitinib/Erlotinib/EGFR gene/mutation-positive引用本文复制引用
谢亚琳,梁继珍,苏宁..吉非替尼与厄洛替尼在EGFR基因敏感突变晚期NSCLC患者一线治疗中的疗效比较[J].南方医科大学学报,2015,(3):446-449,4.基金项目
广州市医药卫生科技项目 （）
